These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25686113)

  • 61. Cancer heterogeneity and drug metabolism: what we know and what we need to know.
    Grizzi F
    Future Oncol; 2016 Jun; 12(11):1317-9. PubMed ID: 27182685
    [No Abstract]   [Full Text] [Related]  

  • 62. Clinical implications of tumor heterogeneity.
    Schilsky RL
    Haematol Blood Transfus; 1987; 31():278-82. PubMed ID: 3327773
    [No Abstract]   [Full Text] [Related]  

  • 63. Tumor metabolism: metabolic alterations and heterogeneity in cancer progression.
    Sebestyén A
    Cancer Metastasis Rev; 2021 Dec; 40(4):987-988. PubMed ID: 34914023
    [No Abstract]   [Full Text] [Related]  

  • 64. On the molecular, cellular and tissue origin of cancer.
    Argenzio E; Klimmeck D
    EMBO J; 2021 Sep; 40(17):e109115. PubMed ID: 34287984
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of genetic targets on cancer therapy. Forward.
    El-Deiry WS
    Adv Exp Med Biol; 2013; 779():v-vi. PubMed ID: 23461003
    [No Abstract]   [Full Text] [Related]  

  • 66. Special issue: Therapy-induced remodeling of the tumor microenvironment.
    Pietras A
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):476. PubMed ID: 35750153
    [No Abstract]   [Full Text] [Related]  

  • 67.
    Oskarsson T
    Am J Physiol Cell Physiol; 2021 Mar; 320(3):C304-C305. PubMed ID: 33264076
    [No Abstract]   [Full Text] [Related]  

  • 68. Commentary: Frailty and cancer.
    Peto J
    Int J Epidemiol; 2015 Aug; 44(4):1423-4. PubMed ID: 25842266
    [No Abstract]   [Full Text] [Related]  

  • 69. Commentary: Frailty and heterogeneity in epidemiological studies.
    Moolgavkar SH
    Int J Epidemiol; 2015 Aug; 44(4):1425-6. PubMed ID: 25878216
    [No Abstract]   [Full Text] [Related]  

  • 70. Clinical significance of intratumor heterogeneity for gynecological carcinoma.
    Yang YC; Li XP
    Chronic Dis Transl Med; 2015 Mar; 1(1):14-17. PubMed ID: 29062982
    [No Abstract]   [Full Text] [Related]  

  • 71. Authors' response: Understanding variation in disease risk.
    Aalen OO; Valberg M; Grotmol T; Tretli S
    Int J Epidemiol; 2015 Aug; 44(4):1426-8. PubMed ID: 25842265
    [No Abstract]   [Full Text] [Related]  

  • 72. Twentieth annual Pezcoller symposium: molecular biology of cancer--20 years of progress punctuated by the Pezcoller symposia.
    Mihich E
    Cancer Res; 2009 Jan; 69(2):407-10. PubMed ID: 19147551
    [No Abstract]   [Full Text] [Related]  

  • 73. Commentary: Age and frailty-not quite the same thing.
    Mathews JD; Hopper JL
    Int J Epidemiol; 2015 Aug; 44(4):1421-3. PubMed ID: 25855711
    [No Abstract]   [Full Text] [Related]  

  • 74. The diverse nature of cancer cells: one reason therapy can fail.
    Macek C
    JAMA; 1982 Jan 22-29; 247(4):417-8. PubMed ID: 7054537
    [No Abstract]   [Full Text] [Related]  

  • 75. Targeting the developmental origins of cancer.
    Skanderup AJ; DasGupta R
    Nat Cancer; 2021 Mar; 2(3):256-257. PubMed ID: 35121958
    [No Abstract]   [Full Text] [Related]  

  • 76. Targeting molecular tumor types.
    Nat Genet; 2013 Oct; 45(10):1103. PubMed ID: 24071840
    [No Abstract]   [Full Text] [Related]  

  • 77. Biochemical uniformity and heterogeneity in cancer tissue (further discussion).
    POTTER VR
    Cancer Res; 1956 Aug; 16(7):658-67. PubMed ID: 13356292
    [No Abstract]   [Full Text] [Related]  

  • 78. Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases.
    Le Pennec S; Konopka T; Gacquer D; Fimereli D; Tarabichi M; Tomás G; Savagner F; Decaussin-Petrucci M; Trésallet C; Andry G; Larsimont D; Detours V; Maenhaut C
    Endocr Relat Cancer; 2015 Apr; 22(2):205-16. PubMed ID: 25691441
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma.
    Grove O; Berglund AE; Schabath MB; Aerts HJ; Dekker A; Wang H; Velazquez ER; Lambin P; Gu Y; Balagurunathan Y; Eikman E; Gatenby RA; Eschrich S; Gillies RJ
    PLoS One; 2015; 10(3):e0118261. PubMed ID: 25739030
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity.
    Aubry M; de Tayrac M; Etcheverry A; Clavreul A; Saikali S; Menei P; Mosser J
    Oncotarget; 2015 May; 6(14):12094-109. PubMed ID: 25940437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.